Abstract:Introduction: Gain-of-function mutations of JAK genes are the main molecular pathogenesis of hematologic malignancies, such as myeloproliferative neoplasm (MPN), polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF) and adult acute lymphocytic leukemia (ALL).Some studies have shown that the constitutive activation of JAK pathway is related to EGFR-TKI resistance in lung cancer patients, but the genomic mutational status of JAK gene family in lung cancer remains unclear.Methods: Totally 14429 patients with lung cancer in China were studied retrospectively; then we analyzed the mutation patterns of JAK family and EGFR gene in tumor tissues and/or liquid biopsy samples of these patients through highthroughput sequencing technology.Results: The mutation frequencies of JAK family genes JAK1, JAK2, and JAK3 in Chinese patients with lung cancer were 0.55% (79/14429), 5.27% (760/14429), and 1.67% (241/ 14429), respectively.Among them, the most common mutations in JAK1 were N339K (5 patients), H183Q (4 patients) and H1072Q (3 patients); the mutations in JAK3 include I688F (19 patients) and A573V (11 patients).Interestingly, the most frequent hotspot mutation of JAK2 gene in lung cancer patients was V617F (87 patients), in line with blood tumors such as MPN.Others were L892Q (19 patients), H848Q (14 patients) and F148I (13 patients).However, in lung cancer, JAK2 mutations mainly occurred in exon 5.It is inconsistent with the locations of JAK2 mutations in blood tumors, which happen largely in exon 12 and exon 16.Studies have found that activation of the JAK pathway can lead to drug resistance in patients with lung cancer who are sensitive to EGFR-TKI, erlotinib.Our analysis found that the frequencies of JAK1 and JAK2 mutations with co-occurring erlotinib-sensitive EGFR common mutations (L858R, exon19 deletion, etc.) were 0.15% (22/14429) and 1.17% (169/14429), respectively.Among them, the proportion of EGFR L858R was the highest (0.10% in JAK1, 0.69% in JAK2).These patients with co-occurring mutations may be resistant to EGFR-TKI such as erlotinib.In addition, other studies found that JAK inhibitors can overcome EGFR-TKI resistance caused by EGFR T790M mutation.Forty-eight patients appeared common EGFR-TKI sensitive mutations, T790M mutations, and JAKs mutations simultaneously (EGFR comutated with JAK1 in 2 patients, with JAK2 in 41 patients, and with JAK3 in 5 patients).Thus, 0.3% lung cancer patients with acquired resistance to EGFR inhibitors may benefit from the combined therapy of JAK inhibitors and EGFR-TKIs.Conclusion: Genomic studies on lung cancer patients in China have found that activation of the JAK signaling pathway is an important molecular biological feature of lung cancer.Gain-of-function mutations of JAKs in lung cancer patients, who harbor epidermal growth factor receptor-activating mutation, may lead to drug resistance to EGFR-TKI.Targeting inhibition of JAK and EGFR may be a new treatment in lung cancer patients with EGFR-TKIs resistance.

EP1.03-01 Molecular Spectrum of Patients with JAK1 Mutations in East Asian Non-Small Cell Lung Cancer

19PJAK3 defines a unique molecular subtypes of East Asian non-small cell lung cancer patients

The Prevalence and Prognostic Significance of JAK2 Mutation Subtypes in Non-Small Cell Lung Cancer from Chinese Populations.

JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer.

The Expression Landscape of JAK1 and Its Potential As a Biomarker for Prognosis and Immune Infiltrates in NSCLC.

EP1.03-35 Prevalence, Clinicopathologic Characteristics, and Molecular Associations of IGF1R Mutations in East Asian Patients with NSCLC

P35.28 WITHDRAWN

EP1.03-07 Prevalence and Clinicopathological Characteristics of EIF1AX Mutations in Chinese Patients with Non-Small Cell Lung Cancer

EP1.03-03 Association Between Molecular Spectrum of EZH2 Variants and Prognosis in Patients with Non-Small-Cell Lung Cancer in Chinese Patients

EP1.03-28 Frequency and Molecular Characteristics of BRCA1 Mutations in Non-Small Cell Lung Cancer from East Asian Patients

P1.03-06 Molecular Landscape of FGFR1 Point Mutations in Chinese Non-Small-Cell Lung Cancer Patients: A Retrospective Study

P1.03-04 Molecular Characteristics of ALK Primary Point Mutations Non-Small-Cell Lung Cancer in Chinese Patients

P1.03-10 the Molecular Spectrum of NF1 Variants in Chinese Non-Small-Cell Lung Cancer Patients

Molecular basis of JAK2 H608Y and H608N mutations in the pathology of acute myeloid leukemia

P1.03-47 KEAP1 Mutations in East Asian Patients with NSCLC: an Investigation of Prevalence, Clinicopathologic Characteristics and Prognosis

EP1.03-18 Analysis of IDH1 Mutation Spectrum from Non-Small-Cell Lung Cancer in East Asian Patients

Table S1, S2, S3 from JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer

P3.03-09 Molecular Spectrum of KIT Mutations Detection in Chinese Non-Small Cell Lung Cancer Patients

P1.02-045 PIK3CA Mutations in Chinese Patients with Non-Small-Cell Lung Cancer

P2.02-007 Molecular Spectrum of STK11 Gene Mutations in Patients with Non-Small-Cell Lung Cancer in Chinese Patients

The Effects of R683S (G) Genetic Mutations on the JAK2 Activity, Structure and Stability.